Welcome to the bioMérieux Clinical Diagnostics website
Send
Send
Print
Print

News

Flux RSS
 
bioMérieux in the News

This section contains recent and past news on bioMérieux in the field of clinical diagnostics and in vitro diagnostic testing.

News items include new product launches, partnerships, acquisitions and agreements, awards for innovation, and highlight bioMérieux’s contribution to in vitro diagnostics in the fields of infectious diseases, cancer and cardiovascular diseases.

You may either browse through the entire list or filter the news items by entering the dates that interest you and clicking on “Go”.

June 6, 2010
Data from Clinical Studies of bioTheranostics’ CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting*
bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company’s CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
Read More
May 25, 2010
bioMérieux Showcases Myla™ at ASM 2010: New Informatics Solution to Transform the Microbiology Laboratory
Innovative solution optimizes laboratory workflow and clinical information management. A world leader in in vitro diagnostics, bioMérieux presented Myla™, a revolutionary new middleware solution to improve connectivity, laboratory workflow and information management, at the 110th General Meeting of the American Society for Microbiology (ASM) in San Diego. Part of bioMérieux’s FMLA™* solutions and services, Myla is an intelligent browser-based application that consolidates and manages microbiology data generated from a variety of sources and converts these data into actionable information for treatment decisions. Designed to transform the way that laboratory managers and technicians work, Myla recaptures time spent on information retrieval and reporting activities through a simple dashboard-based user interface that provides full control of lab workflow.
Read More
May 21, 2010
Shimadzu and bioMérieux Enter into Partnership for Mass Spectrometry Applications in Microbiology
Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimized integration into the microbiology laboratory workflow. This new solution is planned for commercialization by bioMérieux in 2010, together with the microbial database acquired from AnagnosTec.
Read More
May 10, 2010
bioMérieux and GlaxoSmithKline Enter into Alliance to Develop Molecular Theranostic Test for Cancer Treatment Selection
bioMérieux and GlaxoSmithKline (GSK) have signed an agreement to develop a novel molecular test for cancer. In this new collaboration, the two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma (skin cancer).
Read More
April 21, 2010
bioMérieux and Knome Sign Strategic Partnership
Exclusive agreement to bring state-of-the-art genome sequencing technology to the in vitro diagnostics market. bioMérieux takes equity stake in Knome.
Read More
April 12, 2010
bioMérieux Introduces Myla™ at ECCMID: New Informatics Solution to Transform the Microbiology Laboratory
Innovative software:
  • consolidates and transforms microbiology laboratory data into actionable information for treatment decisions
  • recaptures time for lab managers through efficiency gains and full control of lab workflow
A world leader in in vitro diagnostics, bioMérieux presented Myla™, a paradigm-shifting software application, at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria. Myla is a browser-based application that provides microbiology laboratory managers and technicians with a set of tools to revolutionize the way they work. It was designed by microbiologists for microbiologists to recapture the time spent on information retrieving and reporting activities through improved connectivity, laboratory workflow and information management. For more information, visit www.mylahelps.com.
Read More
April 12, 2010
bioMérieux Acquires from AnagnosTec - Database and Expertise for Rapid Microbial Identification Using Mass Spectrometry
bioMérieux announces today that it has agreed on the terms for the acquisition of certain assets from AnagnosTec, a company based in the greater Berlin area, specialized in microbial identification with MALDI-TOF* mass spectrometry technology.
Read More
April 8, 2010
bioMérieux’s PREVI™ Isola Wins the 2010 - Medical Design Excellence Award
The award highlights the automated media streaker’s breakthrough technology.
A world leader in in vitro diagnostics, bioMérieux announced today that its automated media streaker, PREVI™ Isola has received a 2010 Medical Design Excellence Award for contributions and advances in the design of medical products. This exclusive award recognizes products for their design and engineering features, including user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. PREVI Isola was designed to revolutionize front-end media processing tasks, and it is a critical component in bioMérieux’s complete range of solutions and services for Full Microbiology Lab Automation (FMLA™): www.biomerieux-diagnostics.com/fmla
Read More
January 7, 2010
Philips and bioMérieux announce partnership to develop and market next-generation handheld diagnostic solutions for Point-of-Care
Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals.
Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)).
Read More
November 17, 2009
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.
Read More